You just read:

SurgiMab Advances SGM-101, a Novel Fluorescent Tumor-specific Antibody, Into Pivotal Phase 3 Clinical Trial to Improve Surgical Outcomes in Colorectal Cancer Patients

News provided by

SurgiMab

Jul 16, 2019, 03:00 ET